Series C+ · 2026-10-16 · Healthcare
OMass Therapeutics raises $297.0M
74
AI Score
Amount
$297.0M
Round
Series C+
Lead
Bain Capital Life Sciences, Forbion, Novo Holdings
HQ
Oxford, GB
Why it matters: The round shows how European biotech investors are concentrating capital on platform-based drug discovery, with OMass's native mass spectrometry approach now funded through Phase 2.
OMass Therapeutics, a University of Oxford spin-out developing small-molecule drugs.
- Participants:
- Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, University of Oxford
- Source:
- EU-Startups ↗ · Midu summary
Deal Dossier PRO
Pro feature
Deal Dossier for OMass Therapeutics
Company, lead and participating investors, founders, and verified public contact channels — sourced, generated on demand.
Generate dossier — ProFigures marked company-reported are unaudited. Not investment advice. Request a correction or removal (team@midu.si).
Recent Healthcare rounds
Subscribe to the newsletters
Free, by email. No account needed. Pick one or both.
No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.
Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing